Bibliothèque

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few years, the co…

Thérapies de Conversion

Tang, H., Zhang, W., Cao, J., Cao, Y., Bi, X., Zhao, H., Zhang, Z., Liu, Z., Wan, T., Lang, R., Sun, W., Du, S., Yang, Y., Lu, Y., Zeng, D., Wu, J., Duan, B., Lin, D., Li, F., … Editorial, B. o. a. r. d. . o. f. . t. h. e. . C. h. i. n. e. s. e. . J. o. u. r. n. a. l. . o. f. . H. e. p. a. t. o. b. i. l. i. a. r. y. . S. u. r. g. e. r. y. (2025). Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).. Biosci Trends, 18(6), 505-524. https://doi.org/10.5582/bst.2024.01394

14/01/2025 Lire →

Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma.

Recently, a systemic therapy for advanced hepatocellular carcinoma (HCC) has been developed. The regimen for unresectable HCC varies and includes single or multi-tyrosine kinase inhibitors, monoclonal…

Thérapies de Conversion

Hakoda, H., Ichida, A., & Hasegawa, K. (2025). Advances in systemic therapy leading to conversion surgery for advanced hepatocellular carcinoma.. Biosci Trends, 18(6), 525-534. https://doi.org/10.5582/bst.2024.01372

14/01/2025 Lire →

Efficacy of Combined PD-1 Inhibitor and Bevacizumab in Unresectable Liver Metastasis of MSI-H Colorectal Cancer: A Case Report.

BACKGROUND Programmed death 1 (PD-1) inhibitors have demonstrated limited effectiveness in patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC). Recent studies suggest that th…

Thérapies de Conversion

Wang, Q., Zhong, J., Wang, Y., Bao, J., Li, S., & Yang, L. (2025). Efficacy of Combined PD-1 Inhibitor and Bevacizumab in Unresectable Liver Metastasis of MSI-H Colorectal Cancer: A Case Report.. Am J Case Rep, 26, e946757. https://doi.org/10.12659/AJCR.946757

10/01/2025 Lire →

Treatment outcomes and prognostic factors in patients with colorectal cancer and synchronous lung metastases in the conversion therapy era.

PURPOSE: The Japanese Grade Classification based on the status of pulmonary and mesenteric nodal metastases and the presence of extrapulmonary metastases had a prognostic value in patients with colore…

Thérapies de Conversion

Nozawa, H., Suzuki, N., Tsushima, T., Murono, K., Sasaki, K., Emoto, S., Fujishiro, M., Sato, M., & Ishihara, S. (2025). Treatment outcomes and prognostic factors in patients with colorectal cancer and synchronous lung metastases in the conversion therapy era.. Int J Colorectal Dis, 40(1), 9. https://doi.org/10.1007/s00384-024-04799-1

09/01/2025 Lire →

Safety and Efficacy of Conversion Therapy After Systemic Chemotherapy in Advanced Esophageal Cancer with Distant Metastases: A Multicenter Retrospective Observational Study.

BACKGROUND: Patients with esophageal squamous cell carcinoma (ESCC) with distant metastasis were treated with systemic chemotherapy. Recent advances in multimodal treatments have made conversion thera…

Thérapies de Conversion

Tsuji, T., Matsuda, S., Sato, Y., Tanaka, K., Sasaki, K., Watanabe, M., Hamai, Y., Nasu, M., Saze, Z., Nakashima, Y., Nomura, M., Yamamoto, S., Booka, E., Ishiyama, K., Bamba, T., Sakanaka, K., Tsushima, T., Takeuchi, H., Kato, K., & Kawakubo, H. (2025). Safety and Efficacy of Conversion Therapy After Systemic Chemotherapy in Advanced Esophageal Cancer with Distant Metastases: A Multicenter Retrospective Observational Study.. Ann Surg Oncol, 32(1), 274-283. https://doi.org/10.1245/s10434-024-16196-7

01/01/2025 Lire →

Exceptional response to chemo-immunotherapy in a patient with HER2-negative, TMB-high metastatic gastric mucinous adenocarcinoma: a case report and literature review.

Gastric mucinous adenocarcinoma (GMC) is a rare subtype of gastric cancer characterized by excessive mucus production, aggressive biological behavior, and poor prognosis, with most patients presenting…

Thérapies de Conversion

Liu, C., Li, X., Qi, Q., Jing, F., Lv, J., Qiu, W., & Wang, S. (2025). Exceptional response to chemo-immunotherapy in a patient with HER2-negative, TMB-high metastatic gastric mucinous adenocarcinoma: a case report and literature review.. Front Immunol, 16, 1713214. https://doi.org/10.3389/fimmu.2025.1713214

01/01/2025 Lire →

Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer.

BACKGROUND: Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in the treatment of resectable and advanced gastric cancer. However, their effectiveness in initially unresectable gastric ca…

Thérapies de Conversion

Li, S., Xu, Q., Yu, W., Liu, Z., Cui, X., Wei, M., Shi, D., Zhao, W., Song, X., Zhang, D., Nan, Z., Chu, J., Wang, S., Nie, S., Dai, X., & Liu, L. (2025). Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer.. Front Immunol, 16, 1753749. https://doi.org/10.3389/fimmu.2025.1753749

01/01/2025 Lire →

Case Report: Efficacy of preoperative conversion therapy with lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy in an advanced hepatocellular carcinoma.

Advanced hepatocellular carcinoma (HCC) has a poor prognosis. Conversion therapy based on non-surgical local therapy and drug therapy is an effective treatment for unresectable HCC. We report a case o…

Thérapies de Conversion

Mao, J., Zhang, H., Yang, X., Yao, Y., Sun, X., & Yan, Q. (2025). Case Report: Efficacy of preoperative conversion therapy with lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy in an advanced hepatocellular carcinoma.. Front Oncol, 15, 1627281. https://doi.org/10.3389/fonc.2025.1627281

01/01/2025 Lire →

TPF regimen improves conversion surgery and short-term survival in patients with locally unresectable advanced gastric cancer.

OBJECTIVE: To compare the efficacy and safety of TPF versus FOLFOX regimens in conversion therapy for locally unresectable advanced gastric cancer (LAUGC) and to identify prognostic factors influencin…

Thérapies de Conversion

Duan, T., Ma, D., Bai, Z., Ding, X., & Zhang, X. (2025). TPF regimen improves conversion surgery and short-term survival in patients with locally unresectable advanced gastric cancer.. Am J Transl Res, 17(8), 6068-6079. https://doi.org/10.62347/FFQN8329

01/01/2025 Lire →

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IV HER2-positive gastric cancer.

BACKGROUND: Whether the addition of trastuzumab to chemo(immuno)therapy for the preoperative treatment of patients with potentially resectable HER2-positive gastric cancer has clinical benefits remain…

Thérapies de Conversion

Zhang, X., Tian, Y., Wang, H., Song, S., Chen, Y., Liu, N., Zhang, C., Huang, X., Jiang, H., & Hou, H. (2025). Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IV HER2-positive gastric cancer.. Front Immunol, 16, 1624943. https://doi.org/10.3389/fimmu.2025.1624943

01/01/2025 Lire →

Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study.

BACKGROUND: Although immune checkpoint inhibitors (ICIs) and anti-angiogenic drugs have demonstrated effectiveness in treating advanced gastric cancer (GC), their role in neoadjuvant or conversion the…

Thérapies de Conversion

Zhan, Z., Chen, B., Xu, S., Lin, R., Chen, H., Ma, X., Lin, X., Huang, W., Zhuo, C., Chen, Y., & Guo, Z. (2025). Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study.. Front Immunol, 16, 1518217. https://doi.org/10.3389/fimmu.2025.1518217

01/01/2025 Lire →

Recognizing the Role for Conversion Therapy in Metastatic Esophageal Squamous Cell Cancer (ESCC): A Call for Future Study.

Thérapies de Conversion

Baskin, A. S., & Velotta, J. B. (2025). Recognizing the Role for Conversion Therapy in Metastatic Esophageal Squamous Cell Cancer (ESCC): A Call for Future Study.. Ann Surg Oncol, 32(1), 24-26. https://doi.org/10.1245/s10434-024-16335-0

01/01/2025 Lire →